GLP-1 Weight Loss Linked To Dramatically Lower Risk of Sleep Apnea, Kidney Disease and More

A large U.S. real-world study found that more weight loss in the first year of GLP-1 treatment was linked to lower later risk of obesity-related diseases.

Patients taking semaglutide, tirzepatide, or liraglutide who lost the most weight had fewer cases of sleep apnea, chronic kidney disease, osteoarthritis, and heart failure.

People who gained weight after starting treatment generally saw worse outcomes, suggesting benefits depend on actual weight loss, not just drug use.

The findings may help guide long-term obesity care and disease prevention, and were presented at the European Congress on Obesity.